i-Base home
Search Menu
  • Home
  • HTB
  • 2019
  • July
  • 24

HTB

24 July 2019

Contents

Editorial

  • HTB 24 July 2019 online: first reports from IAS 2019

Special reports

  • Fit for purpose 2019 – PDF

Conference reports

  • 10th IAS Conference on HIV Science (IAS 2019) in Mexico City
  • Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals
  • WHO recommends dolutegravir-based ART regimens for all
  • High rates of viral suppression with low dose efavirenz in pregnant Zambian women
  • First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10
  • Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results
  • Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy
  • Fostemsavir: 96-week follow-up in people with multi-drug resistance
  • Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96
  • Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study
  • Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year

PDFs

  • 24 July 2019 vol 20 no 9
  • HTB RSS

Early access

  • Latest update on HIV and COVID-19 from BHIVA and EACS (January 2021) 15 January 2021
  • Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study       14 January 2021
  • Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early 10 January 2021
  • Novavax phase 3 vaccine study launched in the UK, South Africa, US, Mexico and Puerto Rico 10 January 2021
  • All early access reports

Current issues

  • January 2021
  • December 2020
  • November 2020
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook